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Aim. To study the interaction of adaptor protein Ruk/CIN85 SH3 domains with endogenous adaptor protein
Tks4 in normal and tumor cells of different tissue origins. Methods. GST in vitro pull-down assay was performed
using total cell lysates of cell lines of different origins. Results. Using GST in vitro pull-down assay, we have de-
termined that   SH3A domain of adaptor protein Ruk/CIN85 precipitated   full-length form of adaptor protein Tks4
(Mr 120 kDa) from lysates of human breast (MCF-7, MDA-MB-231), melanoma (MM-4), colon (HT-29, DLD-1)
tumor  cells  as well as from lysates of mouse Lewis lung carcinoma cells (LLC) and fibroblasts (NIH 3T3). It has
been also revealed that all Ruk/CIN85 SH3 domains (A, B and C) with high efficiency precipitate the additional
forms of Tks4 with Mr 75, 90 and 160 kDa from lysates of human colon carcinoma cells and mouse fibroblasts. The
molecular nature of new multiple forms of Tks4 has not been determined to date. Conclusions. New multiple mo-
lecular forms of  adaptor protein Tks4 with Mr 75, 90 and 160 kDa, able to interact with high affinity with SH3 do-
mains of Ruk/CIN85, were identified using GST in vitro pull-down assay. The data obtained suggest that inter-
action between    Ruk/CIN85 SH3 domains with   Tks4 endogenous forms  is determined by cellular context while a
level of this interaction can be regulated in the course of  physiological  cellular responses.
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Introduction. Adaptor proteins consist of domains and 
motifs, which mediate intermolecular interactions and
are able to form intracellular protein complexes in a re-
gular and selective manner. It determines their impor-
tant role in the maintenance of specificity and efficien-
cy of all known signal transduction pathways [1]. In par-
ticular, adaptor proteins Ruk/CIN85 (Regulator for ubi-
quitous kinase/Cbl-interacting protein of 85 kDa) and
Tks4 (Tyrosine kinase substrate with 4 SH3 domains)
contain multiple SH3 domains and Pro-rich regions in
their structure [2, 3]. Of note, these adaptor proteins are 
involved in the control of fundamental cellular and sig-
naling events as well as in carcinogenesis [4, 5]. More
than 100 protein partners of  Ruk/CIN85 SH3 domains
were identified in HeLa cells in vitro using the high-
throughput technique combining affinity purification of
interacting partners from cell lysates with liquid chro-
matography-coupled tandem mass spectrometry (LS-
MS/MS). Adaptor protein Tks4 was revealed as one of
the main protein partners according to the number of
unique peptides matching to protein sequence and per-
centage of protein sequence covered by matching pepti-
des. In general, 21 peptides, which overlap 27 % of 911
amino acids of Tks4, were identified [6]. However, no
data regarding the peculiarities of interaction of the indi- 
vidual Ruk/CIN85 SH3 domains with the endogenous
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Tks4 protein in cell context dependent manner have been 
reported so far.
Materials and methods. Cell culture. Cell lines
MCF-7 (human breast adenocarcinoma) and its subline 
G4 (with stable overexpression of adaptor protein Ruk/
CIN85) [7], MDA-MB-231 (human breast adenocarcino- 
ma), LLC (mouse Lewis lung carcinoma), MM-4 (human
melanoma), DLD-1 (human colonic adenocarcinoma),
HT-29 (human colonic adenocarcinoma), NIH 3T3 (mou-
se fibroblasts) were maintained in DMEM («Gibco®»,
USA), containing 10 % fetal bovine serum («HyClone»,
USA), 2 mM glutamine, 50 U/ml penicillin, 50 µg/ml
streptomycin («Gibco®») at 37 °C and 5 % CO2 in a hu-
midified atmosphere. Cells were split 1:3–1:5 every 2–
3 days at 70–80 % confluence.
Preparation of total cell lysates. For obtaining total 
cell lysates, monolayer cultures of cells were washed in 
ice-cold PBS and scraped into lysis buffer (10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 1 % Triton
X-100, 5 mM EDTA supplemented with complete pro-
tease inhibitor cocktail tablet («Roche», France), 1 mM 
sodium orthovanadate, and 1 mM phenylmethylsul-
fonylfuoride (PMSF) («Fluka», Switzerland). The lysa-
tes were kept at 4 °C for 20 min and then were clarified
by centrifugation at 12000 rpm at 4 °C. Protein content
in supernatants was determined using bicinchoninic
acid protein assay kit (Pierce® BCA Protein Assay Kit,
«Thermo Scientific», USA) according to the manufac-
turer’s instructions.
GST in vitro pull-down assay. Plasmids pGEX-4T,
which encode adaptor protein Ruk/CIN85 fragments fu-
sed with the glutathione S-transferase (GST), are descri- 
bed in [8]. 
Single clone of BL21(DE3)pLysS cells («Stratage-
ne», USA) transformed with appropriate plasmid was
resuspended in LB supplemented with 75 µg/ml ampi-
cillin and 34 µg/ml chloramphenicol. Cells were grown 
to OD600 = 0.5–0.6 at 37 °C. 
Expression of recombinant proteins was induced
by 1 mM IPTG (isopropyl-β-D-thiogalactoside) with
further incubation at 25–27 °C for 4 h. Cells were pel-
leted by centrifugation at 3000 rpm, washed with ice-
cold PBS, lysed in appropriate amount of lysis buffer
(see above) at the ratio 1 : 10 for 20 min on ice. Cell lysa- 
tes were sonicated 3 times for 20 s and centrifuged at
12000 rpm at 4 °C for 30 min. 
Supernatants were added to Glutathione-Sepharose 
beads 4B («Amersham Biosciences», USA) in lysis buf- 
fer. Samples were incubated for 2 h at 4 °C. Glutathio-
ne-Sepharose beads were washed by PBS supplemen-
ted with 0.05 % Tween-20 and pelleted by centrifuga-
tion at 2000 rpm for 1–1.5 min. Amount of recombi-
nant proteins bound to Glutathione-Sepharose beads
was verified using SDS-PAGE. For the pull-down expe- 
riments, equal amounts of fusion proteins (about 15 µg at 
density 0.5 µg per 1 µl of Glutathione-Sepharose beads
4B) were used.
Cell lysates (about 1.5 mg of total protein) were in-
cubated with 60 µl of 50 % Glutathione-Sepharose
beads conjugated with corresponding recombinant pro- 
teins. Protein complexes were pelleted by centrifuga-
tion at 3000 rpm. Unbound proteins were removed by
washing the beads 5 times with lysis buffer, whereas
retained proteins were resolved by SDS-PAGE [9] and
analyzed by Western blotting [10]. For detection of Tks4
on blots, the affinity purified polyclonal rabbit antibo-
dies against SH3AB fragment of Tks4 were used. The-
se antibodies were obtained and characterized in our la- 
boratory. Anti-rabbit secondary antibodies (peroxidase-
conjugated IgG from «Sigma», USA) were used. The
enhanced chemiluminescence kit («Amersham Farma-
cia Biotech», USA) was used for detection of immuno-
reactive protein bands. 
Results and discussion. Cell lines of different tis-
sue origins, in particular, MCF-7, MDA-MB 231, HT-29, 
DLD-1, MM-4, NIH 3T3 and LLC were investigated.
According to Fig. 1, the obtained antibodies to SH3AB
fragment of Tks4 (dilution 1:5000) effectively recogni- 
ze the endogenous full-length form of Tks4 (Mr 120 kDa) 
in all analyzed cell lysates. The highest levels  of Tks4
were identified in MDA-MB-231, LLC, MM-4 and
DLD-1 cells, while  lower levels – in MCF-7 and HT-
29 cells. 
Based on these results we can conclude that the
level of Tks4 expression is specific for each cell line
and does not depend on tissue origin. As can be seen in
Fig. 1, the additional form of Tks4 (Mr 160 kDa) is de-
tected in MDA-MB-231, LLC, MM-4, DLD-1 and NIH
3T3 cell lysates.
Progress in the field of functional proteomics du-
ring the last decades is determined by the development
and further improvement of methodological approa-
BAZALII A. V. ET AL.
ches for decoding intermolecular interactions net-
works. It is known that these methods are divided  into 
two groups, synthetic and analytical. GST in vitro pull-
down assay is one of the analytical methods, which allow
identification of the complexes usually purified by affi- 
nity chromatography. The components of purified sup-
ramolecular complexes can be recognized by specific
antibodies or mass-spectrometry. The aim of analytical
methods is the identification of protein partners in cellu-
lo under physiological conditions. As a result, the data
on protein composition of purified complexes provide
an immediate success on the way to the determination
of their functional significance. 
GST-fused SH3A, SH3B, SH3C, SH3AB, SH3BC, 
SH3ABC domains, Pro-rich, Ser-rich, coiled-coil re-
gions, which overlapped all amino acid sequence of
Rukl, were used for GST in vitro pull-down assay. Ac-
cording to the results obtained (Fig. 2), only SH3A
domain precipitates Tks4 from lysates of   breast adeno-
carcinoma (MCF-7 and MDA-MB-231) and melanoma 
(MM-4) cells. In mouse Lewis lung carcinoma cells
(LLC) Tks4 is preferentially precipitated by SH3A do-
main, whereas weak immunoreactive bands are detec-
ted in SH3C- and SH3BC-precipitates. Tks4 is not
detected in SH3B- and SH3AB-precipitates. However,
a significant reduction of Tks4 binding in SH3ABC-
precipitate in comparison with SH3A domain is ob-
served. The performed analysis allows suggesting that
at the level of three-dimensional structure of Ruk/
CIN85 SH3ABC fragment it is SH3B domain that can
screen the binding surface of SH3A domain for Pro-
rich sequences of Tks4 in LLC cells. We also suggest
that phosphorylation of specific Ser/Thr residues loca-
lized in SH3AB domains as well as C-terminally from
Pro-rich region in endogenous Ruk/CIN85 mediated
by input signal may lead to destabilization of its auto-
inhibitory conformation and provides the capacity to form 
complexes with specific binding partners. In mouse fib-
roblasts, the full-length form of Tks4 is mainly preci-
pitated by SH3A and weakly by SH3BC and SH3ABC
domains.
 Interesting results were obtained using pull down as-
say for colonic cell lines such as DLD-1 and HT-29. As
can be seen in Fig. 2, the main Tks4 form (Mr 120 kDa)
is detected only in SH3A-precipitate. Simultaneously,
all used GST-SH3 fragments of Ruk/CIN85 (A, B, C,
AB, BC and ABC) with high efficiency precipitate the
additional form of 90 kDa, the content of which in cells
is extremely low. This form is revealed in Western-
blotting only in the case of increased protein addition
into the pockets of PAA gel. It is possible that the form
with Mr 160 kDa, which is detected in precipitates,
could be a result of posttranslational modification of
Tks4 by ubiquitination or related protein modifications.
New additional form in NIH 3T3 cells is characterized
by higher mobility (Mr about 75 kDa). It is precipitated
by all GST-SH3 fragments of Ruk/CIN85 (A, B, C, AB,
BC and ABC). It should be noted that the high mole-
cular weight form of Tks4 is detected in NIH 3T3 cell
lysates but it is not precipitated by SH3 domains of
Ruk/CIN85. For more careful examination of the speci- 
ficity of the obtained anti-Tks4 polyclonal antibodies,
we performed an antigen competition experiment. For
this purpose, anti-Tks4 antibodies were preincubated
with purified GST-Tks4/SH3AB fragment, and then
this mixture was used for Western blotting of Tks4 en-
dogenous forms. We found that detection of all immu-
noreactive bands was abrogated by antigen competition
(data not shown). 
The molecular nature of new multiple Tks4 forms
with Mr 75, 90 and 160 kDa identified in our study is un-
known. At present there are no data about posttrans-
lational modifications of Tks4 and additional mRNAs,
which could be formed as a result of alternative spli-
cing or alternative promoter usage in TKS4 gene. The
database analysis of expressed sequence tags (ESTs)
allows identifying some ESTs, which could encode the
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Fig. 1. Expression of adaptor protein Tks4 in cell lines of different tis-
sue origins. Immunoblot analysis of cell lysates was performed using
the affinity purified rabbit polyclonal anti-Tks4 antibodies produced
against Tks4 SH3AB fragment
isoforms of Tks4 [11]. However, ESTs are just seg-
ments of corresponding cDNAs. So, further investiga-
tions are necessary to elucidate the mechanisms of ge-
neration and molecular nature of new Tks4 multiple
forms.
Conclusions. New multiple molecular forms of adap- 
tor protein Tks4 with Mr 75, 90 and 160 kDa, which in-
teract with SH3 domains of Ruk/CIN85, were identi-
fied using GST in vitro pull-down assay following by
Western blotting. The capacity of Ruk/CIN85 SH3 do-
mains to interact with multiple endogenous forms of Tks4 
is determined by the cellular context while the level of
their interaction can be regulated in the course of phy-
siological cellular responses.
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Âçàºìîä³ÿ ì³æ àäàï òåð íè ìè á³ëêà ìè Ruk/CIN85 ³ 
Tks4 ó íîð ìàëü íèõ ³ ïóõ ëèí íèõ êë³òè íàõ ð³çíî ãî 
òêà íèí íî ãî ïî õîä æåí íÿ 
À. Â. Áà çàë³é,  À. À. Ñà ìîé ëåí êî, Ä. Ì. Ïå òó õîâ, 
À. Â. Ðèíäè÷, Ì.-É. Ðå äîâ³÷,  Ë. Á. Äðî áîò
Ðå çþ ìå
Ìåòà. Ç’ÿ ñó âà òè îñîá ëè âîñò³ âçàºìîä³¿ îêðå ìèõ  äî ìåí³â SH3 àäàï-
òåðíî ãî á³ëêà Ruk/CIN85 ç åí äî ãåí íèì àäà ïòåðíèì á³ëêîì Tks4 ó
íîð ìàëü íèõ ³ ïóõ ëèí íèõ êë³òè íàõ ð³çíî ãî òêà íèí íî ãî ïî õîä æåí -
íÿ. Ìå òî äè. Àíàë³ç GST in vitro pull-down ïðî âî äè ëè ç âè êî ðèñ òàí-
íÿì çà ãàëü íèõ êë³òèí íèõ ë³çàò³â ë³í³é êë³òèí ð³çíî ãî òêà íèí íî ãî
ïî õîä æåí íÿ. Ðå çóëü òà òè. Âñòà íîâ ëå íî, ùî äî ìåí SH3À àäàï-
òåð íî ãî á³ëêà Ruk/CIN85 ïðå öèï³òóº ïî âíî ðîçì³ðíó ôîð ìó àäàï-
òåð íî ãî á³ëêà Tks4 (Mr 120 êÄà) ç ë³çàò³â ïóõ ëèí íèõ êë³òèí ìî-
ëî÷ íî¿ çà ëî çè (MCF-7, MDA-MB-231), ìå ëà íî ìè (MM-4), îá îäî âî¿
êèø êè (HT-29, DLD-1) ëþ äè íè, à òà êîæ êàð öè íî ìè ëå ãåí³ Ëüþ¿ñ
(LLC) òà ô³áðîá ëàñò³â (NIH 3T3) ìèø³. Âè ÿâ ëå íî òà êîæ, ùî âñ³
äî ìå íè SH3 á³ëêà Ruk/CIN85 (À, Â ³ Ñ) ç âè ñî êîþ åôåê òèâí³ñòþ
ïðå öèï³òó þòü äî äàò êîâ³ ôîð ìè Tks4 ç Mr 75, 90 ³ 160 êÄà ç ë³çà-
ò³â êë³òèí êàð öè íî ìè îá îäî âî¿ êèø êè ëþ äè íè òà ô³áðîá ëàñò³â
ìèø³. Ìî ëå êó ëÿð íó ïðè ðî äó íî âèõ ìíî æèí íèõ ôîðì Tks4 íà ñüî -
ãîäí³ íå âñòàíîâëåíî. Âèñ íîâ êè. ²äåí òèô³êî âà íî íîâ³ ìíî æèíí³
ìî ëå êó ëÿðí³ ôîð ìè àäà ïòåðíî ãî á³ëêà Tks4 ç Mr 75, 90 ³ 160 êÄà,
çäàòí³ ç âè ñî êîþ àô³íí³ñòþ âçàºìîä³ÿòè ç äî ìå íà ìè SH3 á³ëêà
Ruk/CIN85. Îòðè ìàí³ äàí³ äîç âî ëÿ þòü ïðè ïóñ òè òè, ùî ìîæ ëè-
â³ñòü çâ’ÿ çó âàí íÿ äî ìåí³â SH3 Ruk/CIN85 ç åí äî ãåí íè ìè ôîð ìà ìè 
á³ëêà Tks4 îá óìîâ ëå íà êë³òèí íèì êîí òåê ñòîì, òîä³ ÿê ð³âåíü âçàº-
ìîä³¿ ðå ãó ëþºòüñÿ â ïðî öåñ³ ðåàë³çàö³¿ ô³ç³îëîã³÷íèõ â³äïîâ³äåé
êë³òèí.
Êëþ ÷îâ³ ñëî âà: àäàï òåðí³ á³ëêè, Ruk/CIN85, Tks4, äî ìå íè SH3,
àíàë³ç GST in vitro pull-down.
Âçà è ìî äå éñòâèå ìåæ äó àäàï òåð íû ìè áåë êà ìè Ruk/CIN85 
è Tks4 â íîð ìàëü íûõ è îïó õî ëå âûõ êëåò êàõ ðàç ëè÷ íî ãî 
òêà íå âî ãî ïðî èñ õîæ äå íèÿ 
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Öåëü. Âû ÿñ íèòü îñî áåí íîñ òè âçà è ìî äå éñòâèÿ îò äåëü íûõ äî ìå -
íîâ SH3 àäà ïòåðíî ãî áåë êà Ruk/CIN85 ñ ýí äî ãåí íûì àäàïòåð-
íûì áåë êîì Tks4 â íîð ìàëü íûõ è îïó õî ëå âûõ êëåò êàõ ðàç íî ãî òêà-
íå âî ãî ïðî èñ õîæ äå íèÿ. Ìå òî äû. Àíàëèç GST in vitro pull-down
ïðî âî äè ëè ñ èñ ïîëü çî âà íè åì îá ùèõ êëå òî÷ íûõ ëè çà òîâ ëè íèé êëå- 
òîê ðàç íî ãî òêà íå âî ãî ïðî èñ õîæ äå íèÿ. Ðå çóëü òà òû. Óñòà íîâ ëå-
íî, ÷òî äî ìåí SH3À àäà ïòåðíî ãî áåë êà Ruk/CIN85 ïðå öè ïè òè ðó -
åò ïî ëíî ðàç ìåð íóþ ôîð ìó àäà ïòåðíî ãî áåë êà Tks4 (Mr 120 êÄà)
èç ëè çà òîâ îïó õî ëå âûõ êëå òîê ìî ëî÷ íîé æå ëå çû (MCF-7, MDA-
MB-231), ìå ëà íî ìû (MM-4), îá îäî÷ íîé êèø êè (HT-29, DLD-1) ÷å-
ëî âå êà, à òàê æå êàð öè íî ìû ëåã êî ãî Ëüþ èñ (LLC) è ôèá ðîá ëàñ òîâ
(NIH 3T3) ìûøè. Âû ÿâ ëå íî òàê æå, ÷òî âñå äî ìå íû SH3 áåë êà
Ruk/CIN85 (À, Â è Ñ) ñ âû ñî êîé ýô ôåê òèâ íîñ òüþ ïðå öè ïè òè ðó -
þò äî ïîë íè òåëü íûå ôîð ìû Tks4 ñ Mr 75, 90 è 160 êÄà èç ëè çà òîâ
êëå òîê êàð öè íî ìû îá îäî÷ íîé êèø êè ÷å ëî âå êà è ôèá ðîá ëàñ òîâ
ìûøè. Ìî ëå êó ëÿð íàÿ ïðè ðî äà íî âûõ ìíî æåñ òâåí íûõ ôîðì Tks4
íà ñå ãî äíÿ íå óñòà íîâ ëå íà. Âû âî äû. Ïðè ïî ìî ùè àíà ëè çà GST in
vitro pull-down èäåí òè ôè öè ðî âà íû íî âûå ìíî æåñ òâåí íûå ìî ëå -
êó ëÿð íûå ôîð ìû àäà ïòåðíî ãî áåë êà Tks4 ñ Mr 75–90 è 160 êÄà,
ñïîñî áíûå ñ âû ñî êîé àô ôèí íîñ òüþ âçà è ìî äå éñòâî âàòü ñ äî ìå íà- 
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Fig. 2. SH3 domains of Ruk/CIN85 precipitate multiple forms of endo- 
genous protein Tks4 from cell lysates of different tissue origins. Wes-
tern blotting was performed using the polyclonal anti-Tks4 antibodies
(1:5000). TCL – total cell lysate; GST – Glutathione-S-Transferase
ìè SH3 áåë êà Ruk/CIN85. Ïî ëó ÷åí íûå äàí íûå ïî çâî ëÿ þò ïðåä ïî -
ëî æèòü, ÷òî âîç ìîæ íîñòü âçà è ìî äå éñòâèÿ äî ìå íîâ SH3 áåë êà
Ruk/CIN85 ñ ýí äî ãåí íû ìè ôîð ìà ìè áåë êà Tks4 îïðå äå ëÿ åò ñÿ êëå -
òî÷ íûì êîí òåê ñòîì, â òî âðå ìÿ êàê óðî âåíü ñâÿ çû âà íèÿ ðå ãó ëè -
ðó åò ñÿ â ïðî öåñ ñå ðå à ëè çà öèè ôè çè î ëî ãè ÷åñ êèõ îò âå òîâ êëå òîê.
Êëþ ÷å âûå ñëî âà: àäà ïòåðíûå áåë êè, Ruk/CIN85, Tks4, äî ìå íû
SH3, àíà ëèç GST in vitro pull-down.
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